Mark de Boer
Dr. Mark de Boer (CEO) is an independent serial biotech entrepreneur and founded several successful biotech companies. He has been a Venture Partner for more than 10 years at Index Ventures and Medicxi. His investments include Molecular Partners, PanGenetics (acquired by Abbott), ProFibrix (acquired by The Medicines Company) and Versartis. Mark graduated in Biochemistry and has a PhD from the University of Amsterdam. He has worked for, managed and founded a number of early-stage biopharmaceutical companies in the field of innovative novel biopharmaceuticals, including EnCare Biotech and Gadeta.
Chairman of the Board
Mikael Ørum holds more than 35 years of executive experience in the pharmaceutical, biotech and finance sectors. In 1995, Mikael Ørum co-founded Exiqon A/S. The company listed in 2007 on the Nasdaq Copenhagen stock exchange. In 2016, the company was acquired by Qiagen. In 2000, he spun-out the therapeutic rights of Exiqon’s broad RNA/DNA platform (Locked Nucleic Acid) to Santaris Pharma A/S that was sold to F. Hoffmann-La Roche in 2014. It now operates as Roche Innovation Center Copenhagen.
In 2002, Mikael Ørum founded Ventac Partners, an international partnership with offices in the USA, Europe and Asia focusing on building and managing biotech and medtech companies from start to exit. He has been co-founding eight companies since.
Mikael Ørum currently serves as CEO and Chairman (and Co-founder) of Avexxin AS (Norway), a clinical stage therapeutic company addressing chronic inflammatory disorders. In addition, he serves as Chairman or Board Member of several international biotech companies, including RhoVac AB (listed on a Swedish stock exchange), Neuroscience Technologies S.L.P. (Spain) and Neuroscience Technology Limited (UK), Amunix Operating, Inc, (USA) and a US start-up company Orbit Genomics, Inc.
Mikael Ørum has served on the Scientific Advisory Board of Virginia Bioinformatics Institute, Virginia Polytechnic Institute and State University (Virginia Tech) (USA), as Advisory Board Member of the Institute of Nanotechnology and Council Member at the Danish Technical University and as Vice Chairman of Medicon Valley Alliance representing one of the largest biotech and medtech clusters in Europe comprising more than 300 life sciences companies in the greater Copenhagen Area (Capital of Denmark) and the southern part of Sweden.
Mikael Ørum holds an education in banking, finance and law from Copenhagen Business School, Danish Bankers Academy, Copenhagen Business College and Copenhagen University. Furthermore, he has military training and an officer’s education from the Royal Danish Guard and Home Guard Region VI. He served for a number of years as a Staff Officer in the Military Command of Greater Copenhagen.
Volker Schellenberger, Ph.D.
CEO and President
Dr. Volker Schellenberger is a co-founder of Amunix and currently serves as CEO and President. Dr. Schellenberger has extensive industry experience in protein engineering and drug discovery. Previously, he headed the Protein Engineering department at Genencor, where he invented combinatorial consensus mutagenesis, selection by micro-compartmentalization, as well as mutator technology. In addition, he initiated and led collaborations with Seattle Genetics that focused on antibody-enzyme fusion proteins. Prior to his work on biotherapeutics, Dr. Schellenberger directed projects optimizing enzymes for industrial applications as well as microbes for metabolic pathway engineering.
Dr. Schellenberger received his Ph.D. from Leipzig University, where he studied protease catalyzed peptide synthesis. After postdoctoral studies at the Institute for Protein Research in Pushchino (Russia), he moved to the University of Göttingen where he developed a novel method for the production of peptides from recombinant peptide-multimers. After a postdoctoral fellowship with Bill Rutter at the University of California, San Francisco, Dr. Schellenberger joined Genencor in 1994. Dr. Schellenberger is the author of over 40 scientific papers and an inventor on more than 70 issued and pending patent applications. He is also the recipient of the Karl Lohman award of the German Society of Biochemists.
Michael Scholle is currently Founder and Vice President of Operations and Technology at SAMDI Tech Inc. He was previously Scientist and Manager of Operations at Amunix from 2006 to 2009, where he played an early role in the development of Amunix’s XTEN technology. From 2002 to 2006, he held scientific positions at Argonne National Laboratory, where he pioneered phage display for applications in antibody generation and diagnostics. From 2001 to 2002, he was a project lead at Integrated Genomics, where he discovered several novel antimicrobial drug targets using whole genome transposon mutagenesis.
Mr. Scholle received his B.S. and M.S. degrees from Northern Illinois University, where he studied DNA transfer and spore formation in Bacillus. He also holds an M.B.A. from Roosevelt University of Chicago. Mr. Scholle has over 20 scientific publications and book chapters.